Squarer Ron

SEC source: 0001193125-26-305080 · ownership.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 4,418 shares

Expires 2035-12-10

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

SEC source: 0001193125-26-305080 · ownership.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"),

F2 · kind: (Continued from footnote 1) subject to applicable withholding tax. After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F3 · kind: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.

F4 · kind: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

F4 · shares: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

F4 · price: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

SEC source: 0001454001-26-000004 · ownership.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,281

F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001628280-26-040492 · wk-form4_1780520606.xml · nonDerivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,431

F2 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

SEC source: 0001628280-26-040492 · wk-form4_1780520606.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,627

F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001454001-26-000002 · form4-05212026_050515.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2036-05-19

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001454001-26-000002 · form4-05212026_050515.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,375

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001193125-25-316060 · ownership.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,418

Underlying: Class A Common Stock · 4,418 shares

Expires 2035-12-10

F2 · derivative.exercise_date: The shares underlying this option vest over the three years following December 10, 2025, in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001193125-25-316060 · ownership.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,837

F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following December 10, 2025, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

SEC source: 0001628280-25-031895 · wk-form4_1750194217.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,627

F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

SEC source: 0001628280-25-029724 · wk-form4_1749157450.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,811

F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001415889-25-013503 · form4-05162025_070517.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-05-15

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-25-013503 · form4-05162025_070517.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,375

F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001628280-24-028987 · wk-form4_1718760917.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,663

F1 · kind: Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units.

SEC source: 0001628280-24-028343 · wk-form4_1718400349.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,658

F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-24-072199 · ownership.xml · derivative · entry 5

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,727 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072199 · ownership.xml · derivative · entry 4

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072199 · ownership.xml · derivative · entry 3

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,269 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072199 · ownership.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072199 · ownership.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,570 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0001415889-24-012851 · form4-05102024_040553.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-24-012851 · form4-05102024_040553.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0000950170-24-005386 · ownership.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,727

Underlying: Common Stock · 4,727 shares

Expires 2034-01-15

F1 · price: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2024 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024.

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2024 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024.

SEC source: 0001209191-23-039329 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-20

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 21, 2024, subject to continued service through such date.

SEC source: 0001209191-23-030950 · doc4.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030950 · doc4.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,375

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-003993 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,269

Underlying: Common Stock · 3,269 shares

Expires 2033-01-16

F1 · price: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.

SEC source: 0001209191-22-039198 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2032-06-22

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2023, subject to continued service through such date.

SEC source: 0001209191-22-028703 · doc4.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2032-05-10

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-22-028703 · doc4.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-22-004082 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,570

Underlying: Common Stock · 9,570 shares

Expires 2032-01-17

F1 · price: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022.

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022.

SEC source: 0001209191-21-043272 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2031-06-22

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2022, subject to continued service through such date.

SEC source: 0001209191-21-033845 · doc4.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2031-05-13

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-21-033845 · doc4.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-21-004247 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,563

Underlying: Common Stock · 1,563 shares

Expires 2031-01-14

F1 · price: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2021 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 391 shares will vest on March 31, 2021, 391 shares will vest on June 30, 2021, 391 shares will vest on September 30, 2021 and the remaining 390 shares will vest on December 31, 2021.

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2021 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 391 shares will vest on March 31, 2021, 391 shares will vest on June 30, 2021, 391 shares will vest on September 30, 2021 and the remaining 390 shares will vest on December 31, 2021.

SEC source: 0001209191-20-042771 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2030-07-15

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee for the second half of 2020 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy and 362 shares will vest on September 30, 2020 and 361 shares will vest on December 31, 2020, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

SEC source: 0001209191-20-036236 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 10, 2021, subject to continued service through such date.

SEC source: 0001209191-20-030750 · doc4.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2030-05-14

SEC source: 0001209191-20-030750 · doc4.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,875

SEC source: 0001209191-19-059467 · doc4.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2029-12-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option will vest in equal monthly installments over a three-year period, subject to a continued service relationship through such dates.

SEC source: 0001209191-20-011032 · doc4a.xml · derivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,900

Underlying: Common Stock · 21,900 shares

Expires 2029-12-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option will vest in equal monthly installments over a three-year period, subject to a continued service relationship through such dates.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 9

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 678,750 shares

Expires 2028-12-16

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F11 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 8

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 600,000 shares

Expires 2027-12-16

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F10 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 16, 2018.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 7

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 421,875 shares

Expires 2026-12-27

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F9 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 26, 2017.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 6

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 453,750 shares

Expires 2026-04-01

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F8 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2017.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 5

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 113,438 shares

Expires 2025-04-01

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F7 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2016.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 4

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 345,312 shares

Expires 2024-04-01

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2015.

SEC source: 0001209191-19-043786 · doc4.xml · derivative · entry 3

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 545,820 shares

Expires 2022-04-26

F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F4 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 26, 2013.

SEC source: 0001209191-19-043786 · doc4.xml · nonDerivative · entry 2

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3 · price: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

SEC source: 0001209191-19-043786 · doc4.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 442,190

F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.